Home・Elenco Azioni・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Chiusa

SettoreSettore sanitario

72.09 -0.47

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

71.83

Massimo

72.67

Metriche Chiave
By Trading Economics
Entrata	11M -156M
Vendite	28M 222M
EPS	-0.78
Margine di Profitto	-70.082
Dipendenti	999
EBITDA	-24M -137M

Dividendi
By Acuity
Utili prossimi	28 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-2B 15B
Apertura precedente	72.56
Chiusura precedente	72.09

Notizie sul Sentiment di mercato

By Acuity

72%

28%

301 / 339 Classifica in Healthcare

Bridgebio Pharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 set 2026, 19:56 UTC

News

Social Media

BBIO lower as JPMorgan cuts price target to $23.00.

10 set 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering sharply despite being below its 20-day moving average and near a one-month low.

9 set 2026, 22:46 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, despite no specific news. Broader market pressure persists from rising crude oil prices above $100.

2 set 2026, 19:36 UTC

Social Media

News

Event

BridgeBio Pharma will present new infigratinib data at a pediatric endocrinology meeting in September. HC Wainwright maintains a Buy rating and $120 price target.

1 set 2026, 23:16 UTC

News

BridgeBio Pharma shares are lower in after-market hours following a $500 million mixed securities shelf filing, raising concerns about potential dilution.

28 ago 2026, 20:08 UTC

Social Media

BridgeBio Pharma Inc's shares are lower today, continuing a downward trend despite positive social media discussions regarding its treatment, Attruby, based on WF's analysis.

20 ago 2026, 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

19 ago 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18 ago 2026, 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14 ago 2026, 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13 ago 2026, 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12 ago 2026, 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11 ago 2026, 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10 ago 2026, 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7 ago 2026, 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6 ago 2026, 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5 ago 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4 ago 2026, 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3 ago 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31 lug 2026, 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30 lug 2026, 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29 lug 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28 lug 2026, 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27 lug 2026, 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Confronto tra pari

Modifica del prezzo

Bridgebio Pharma Inc Previsione

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

17 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 17 che hanno fornito valutazioni azionarie a Bridgebio Pharma Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

301 / 339 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.